Description of Invention: Current invention describes the methods to prepare vaccines, and to use such vaccines in the vaccination and treatment of human disease, e.g., the human immunodeficiency virus (HIV) infections and cancer. More specifically, the present invention provides a vaccine and method for making same which is effective to elicit a desired antibody against a target antigen comprising a primary immunogen and a secondary immunogen, wherein the primary immunogen is effective to elicit B cell receptors (BCRs) that are on the maturational pathway of the desired antibody and have an intermediate degree of somatic mutational diversity, and the secondary immunogen comprises an epitope of the desired target antibody and is effective to further diversify the BCRs sufficient to form mature BCRs having the identical or substantially identical sequence as the desired antibody.
Applications: Treatment and prevention of HIV infection
Advantages:
Novel methods to design vaccines for HIV treatment and prevention
May also be used for designing vaccines for cancer treatment
Collaborative Research Opportunity: The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this method. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
For Licensing Information Please Contact: Sally Hu Ph.D., M.B.A. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 21, Rockville, MD 20852 United States Email: hus@mail.nih.gov Phone: 301-435-5606 Fax: 301-402-0220
Description of Invention:
Current invention describes the methods to prepare vaccines, and to use such vaccines in the vaccination and treatment of human disease, e.g., the human immunodeficiency virus (HIV) infections and cancer. More specifically, the present invention provides a vaccine and method for making same which is effective to elicit a desired antibody against a target antigen comprising a primary immunogen and a secondary immunogen, wherein the primary immunogen is effective to elicit B cell receptors (BCRs) that are on the maturational pathway of the desired antibody and have an intermediate degree of somatic mutational diversity, and the secondary immunogen comprises an epitope of the desired target antibody and is effective to further diversify the BCRs sufficient to form mature BCRs having the identical or substantially identical sequence as the desired antibody.
Applications:
Treatment and prevention of HIV infection
Advantages:
Development Status:
In vitro data available
Inventors:
Dimiter S Dimitrov (NCI)
Patent Status:
HHS, Reference No. E-322-2008/0
PCT, Application No. PCT/US2009/60303 filed 11 Oct 2009
US, Application No. 13/123,659 filed 11 Apr 2011
Relevant Publication:
Collaborative Research Opportunity:
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this method. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
For Licensing Information Please Contact:
Sally Hu Ph.D., M.B.A.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 21,
Rockville, MD 20852
United States
Email: hus@mail.nih.gov
Phone: 301-435-5606
Fax: 301-402-0220
Ref No: 1899
Updated: 09/2012